154 related articles for article (PubMed ID: 35949061)
21. Gastrointestinal stromal tumors with BRAF gene fusions. A report of two cases showing low or absent KIT expression resulting in diagnostic pitfalls.
Torrence D; Xie Z; Zhang L; Chi P; Antonescu CR
Genes Chromosomes Cancer; 2021 Dec; 60(12):789-795. PubMed ID: 34398495
[TBL] [Abstract][Full Text] [Related]
22. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.
Jiao Y; Yonescu R; Offerhaus GJ; Klimstra DS; Maitra A; Eshleman JR; Herman JG; Poh W; Pelosof L; Wolfgang CL; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N; Wood LD
J Pathol; 2014 Mar; 232(4):428-35. PubMed ID: 24293293
[TBL] [Abstract][Full Text] [Related]
23. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
24. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
25. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
26. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.
Tomić TT; Olausson J; Wilzén A; Sabel M; Truvé K; Sjögren H; Dósa S; Tisell M; Lannering B; Enlund F; Martinsson T; Åman P; Abel F
PLoS One; 2017; 12(4):e0175638. PubMed ID: 28448514
[TBL] [Abstract][Full Text] [Related]
27. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
28. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
Ross JS; Wang K; Chmielecki J; Gay L; Johnson A; Chudnovsky J; Yelensky R; Lipson D; Ali SM; Elvin JA; Vergilio JA; Roels S; Miller VA; Nakamura BN; Gray A; Wong MK; Stephens PJ
Int J Cancer; 2016 Feb; 138(4):881-90. PubMed ID: 26314551
[TBL] [Abstract][Full Text] [Related]
29. PIN-like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations.
Kaur HB; Salles DC; Paulk A; Epstein JI; Eshleman JR; Lotan TL
Histopathology; 2021 Jan; 78(2):327-333. PubMed ID: 32740981
[TBL] [Abstract][Full Text] [Related]
30. Diverse
Stangl C; Post JB; van Roosmalen MJ; Hami N; Verlaan-Klink I; Vos HR; van Es RM; Koudijs MJ; Voest EE; Snippert HJG; Kloosterman WP
Mol Cancer Res; 2020 Apr; 18(4):537-548. PubMed ID: 31911540
[TBL] [Abstract][Full Text] [Related]
31. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
32. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children.
Cordioli MI; Moraes L; Bastos AU; Besson P; Alves MT; Delcelo R; Monte O; Longui C; Cury AN; Cerutti JM
Thyroid; 2017 Feb; 27(2):182-188. PubMed ID: 27849443
[TBL] [Abstract][Full Text] [Related]
33. Excellent Response to MEK Inhibition in an
Domen A; Paesschen CV; Zwaenepoel K; Lambin S; Pauwels P; Rasschaert M; Segelov E; Peeters M; Prenen H
Anticancer Res; 2022 Jan; 42(1):373-379. PubMed ID: 34969747
[TBL] [Abstract][Full Text] [Related]
34. Pathology and genetics of pancreatic neoplasms with acinar differentiation.
Wood LD; Klimstra DS
Semin Diagn Pathol; 2014 Nov; 31(6):491-497. PubMed ID: 25441307
[TBL] [Abstract][Full Text] [Related]
35. Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population.
Gertz RJ; Nikiforov Y; Rehrauer W; McDaniel L; Lloyd RV
Arch Pathol Lab Med; 2016 Feb; 140(2):134-9. PubMed ID: 26910217
[TBL] [Abstract][Full Text] [Related]
36. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features.
Thompson ED; Wood LD
Arch Pathol Lab Med; 2020 Jul; 144(7):808-815. PubMed ID: 31869246
[TBL] [Abstract][Full Text] [Related]
38. Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.
Allen A; Qin ACR; Raj N; Wang J; Uddin S; Yao Z; Tang L; Meyers PA; Taylor BS; Berger MF; Yaeger R; Reidy-Lagunes D; Pratilas CA
PLoS One; 2019; 14(6):e0217399. PubMed ID: 31158244
[TBL] [Abstract][Full Text] [Related]
39. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].
Zhu XL; Zhou XY; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547
[TBL] [Abstract][Full Text] [Related]
40. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
